NEW YORK – A public-private partnership in Oklahoma is gearing up to begin high-throughput molecular diagnostic testing for COVID-19 using Fluidigm's microfluidic technology, the partners said on Thursday.
The real-time PCR test, developed by the nonprofit Oklahoma Medical Research Foundation and the University of Oklahoma Health Sciences Center, will run on Fluidigm's Biomark HD system and is intended for large-scale testing of patients across the OU Medicine healthcare system and, eventually, the entire state, stakeholders said in a webcast announcing the initiative on Thursday.